Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 6.27
-0.22 (-3.39%)
Jun 18, 2026, 2:54 PM CST
Merdury Biopharmaceutical Company Description
Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan.
The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development.
It also offers formulation design and 3D pharmaceutical processing services. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.
Merdury Biopharmaceutical Corporation
| Country | Taiwan |
| Founded | 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Yaoren Liang |
Contact Details
Address: No. 653, Bannan Rd. New Taipei City, 235030 Taiwan | |
| Phone | 886 2 8221 2020 |
| Website | merdury.com |
Stock Details
| Ticker Symbol | 6932 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006932007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yaoren Liang | GM and Director |
| Chun Chun Zhang | Vice President of Administration and Accounting Supervisor |
| Ruixing Chen | Legal Director and Director |
| Nanxiong Zhang | Chief Marketing Officer and Director |
| Chaoyi Chen | Chief Research and Development Officer |